Oncology & Hematology Coding Alert

Reader Questions:

Zero In on Xerostomia Coding

Question: If we provide amifostine for a lip cancer patient receiving radiation, which diagnosis codes should we report? Florida Subscriber Answer: For many payers, reporting the radiation encounter (V58.0, Encounter for other and unspecified procedures and aftercare; radiotherapy) and the appropriate neoplasm code (140.x, Malignant neoplasm of lip) will suffice to prove amifostine (J0207, Injection,amifostine, 500 mg) medically necessary. Check your payer policies to get the final word on which codes -- supported by your documentation -- the payer requires on the claim for payment. For example, the First Coast Service Options local coverage  determination (LCD) for amifostine (L29059) states that Medicare will consider amifostine medically reasonable and necessary "to reduce the incidence of moderate to severe xerostomia in patients undergoing radiation treatment for head and neck cancers where the radiation port includes a substantial portion of the parotid gland." In addition to the appropriate head and neck cancer codes, other codes [...]
You’ve reached your limit of free articles. Already a subscriber? Log in.
Not a subscriber? Subscribe today to continue reading this article. Plus, you’ll get:
  • Simple explanations of current healthcare regulations and payer programs
  • Real-world reporting scenarios solved by our expert coders
  • Industry news, such as MAC and RAC activities, the OIG Work Plan, and CERT reports
  • Instant access to every article ever published in Revenue Cycle Insider
  • 6 annual AAPC-approved CEUs
  • The latest updates for CPT®, ICD-10-CM, HCPCS Level II, NCCI edits, modifiers, compliance, technology, practice management, and more